Skye Bioscience (SKYE) Competitors $4.75 +0.26 (+5.79%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.01 +0.26 (+5.56%) As of 06:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. CMPX, SLDB, OCGN, CYRX, MLTX, GLUE, ADCT, KRRO, PRTC, and AUTLShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Compass Therapeutics (CMPX), Solid Biosciences (SLDB), Ocugen (OCGN), CryoPort (CYRX), MoonLake Immunotherapeutics (MLTX), Monte Rosa Therapeutics (GLUE), ADC Therapeutics (ADCT), Korro Bio (KRRO), PureTech Health (PRTC), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Its Competitors Compass Therapeutics Solid Biosciences Ocugen CryoPort MoonLake Immunotherapeutics Monte Rosa Therapeutics ADC Therapeutics Korro Bio PureTech Health Autolus Therapeutics Skye Bioscience (NASDAQ:SKYE) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends. Does the media favor SKYE or CMPX? In the previous week, Skye Bioscience had 13 more articles in the media than Compass Therapeutics. MarketBeat recorded 14 mentions for Skye Bioscience and 1 mentions for Compass Therapeutics. Skye Bioscience's average media sentiment score of 1.08 beat Compass Therapeutics' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SKYE or CMPX? Skye Bioscience currently has a consensus target price of $14.75, suggesting a potential upside of 210.53%. Compass Therapeutics has a consensus target price of $13.88, suggesting a potential upside of 275.00%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Compass Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more volatility & risk, SKYE or CMPX? Skye Bioscience has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Is SKYE or CMPX more profitable? Compass Therapeutics' return on equity of -53.11% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -76.03% -69.20% Compass Therapeutics N/A -53.11%-46.14% Which has preferable earnings & valuation, SKYE or CMPX? Compass Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$1.06-4.48Compass TherapeuticsN/AN/A-$49.38M-$0.45-8.22 Do insiders and institutionals hold more shares of SKYE or CMPX? 21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 4.5% of Skye Bioscience shares are owned by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCompass Therapeutics beats Skye Bioscience on 8 of the 13 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.19M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-4.4822.2887.1026.71Price / SalesN/A265.39538.92204.35Price / CashN/A46.3226.3031.09Price / Book2.119.9012.696.57Net Income-$26.57M-$52.45M$3.30B$276.78M7 Day Performance22.42%5.05%3.53%1.96%1 Month Performance18.75%10.61%6.74%9.11%1 Year Performance33.80%25.03%72.67%31.60% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience2.4414 of 5 stars$4.75+5.8%$14.75+210.5%+33.8%$147.19MN/A-4.4811Positive NewsCMPXCompass Therapeutics1.952 of 5 stars$3.50-8.4%$13.88+296.4%+91.7%$483.99MN/A-7.7820Positive NewsHigh Trading VolumeSLDBSolid Biosciences3.0751 of 5 stars$6.17+3.4%$15.00+143.1%-10.3%$480.46M$8.09M-2.20100OCGNOcugen1.7162 of 5 stars$1.63+12.4%$6.00+268.1%+75.2%$476.45M$4.05M-8.1580CYRXCryoPort3.951 of 5 stars$9.48+0.7%$12.56+32.4%+22.7%$474.64M$237.88M7.131,186Positive NewsMLTXMoonLake Immunotherapeutics2.9711 of 5 stars$7.17+14.9%$43.82+511.1%-84.8%$460.54MN/A-2.582Trending NewsAnalyst RevisionHigh Trading VolumeGLUEMonte Rosa Therapeutics2.9257 of 5 stars$7.41+1.4%$15.33+106.9%+52.1%$457.63M$177.99M20.5890Positive NewsADCTADC Therapeutics2.9259 of 5 stars$4.02flat$7.75+92.8%+24.7%$452.25M$70.84M-2.56310News CoveragePositive NewsAnalyst RevisionHigh Trading VolumeKRROKorro Bio1.5397 of 5 stars$47.89+11.9%$86.83+81.3%+37.6%$449.69M$2.27M-4.9170News CoverageHigh Trading VolumePRTCPureTech Health0.0726 of 5 stars$18.37+1.8%N/A-6.6%$443.99M$6.17M0.00100Positive NewsGap UpAUTLAutolus Therapeutics3.5645 of 5 stars$1.63+2.5%$9.12+459.5%-59.5%$433.81M$10.12M-1.94330Positive News Related Companies and Tools Related Companies CMPX Alternatives SLDB Alternatives OCGN Alternatives CYRX Alternatives MLTX Alternatives GLUE Alternatives ADCT Alternatives KRRO Alternatives PRTC Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
